Jun 30, 2021 · In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and ...
Mar 4, 2021 · Overall, the published trials and retrospective series indicated that daratumumab is highly effective also in relapsed/refractory patients with ...
People also ask
Is daratumumab approved for amyloidosis?
How do you treat amyloid light chain AL amyloidosis?
What chemotherapy is used for light chain amyloidosis?
What is the mechanism of action of daratumumab in amyloidosis?
Dec 1, 2022 · Daratumumab-based regimens achieve deep hematologic and organ responses, offering a new therapeutic backbone. Early identification, correct ...
Jul 1, 2021 · Daratumu- mab, a human CD38-targeting antibody, may improve outcomes for this disease. METHODS. We randomly assigned patients with newly ...
Apr 9, 2024 · Our data suggest that continuing daratumumab with the addition of IMiDs (pomalidomide, lenalidomide) and/or the second-generation proteasome ...
Jul 4, 2022 · Intravenous daratumumab (DARA IV) has been increasingly used in the treatment of amyloid light-chain (AL) amyloidosis.
Daratumumab proved to be highly effective in newly diagnosed AL amyloidosis with excellent hematologic and organ response rates, a remarkable safety profile, ...
Mar 17, 2022 · In patients with relapsed or refractory AL amyloidosis, daratumumab has shown promising efficacy in terms of hematologic responses and ...
Dec 13, 2021 · The use of daratumumab, a human anti-CD38 monoclonal antibody, has shown important efficacy with minor toxicities in patients with relapsed or refractory AL ...
Aug 14, 2023 · As daratumumab use in AL amyloidosis increases, more patients will either relapse after or become refractory to daratumumab.
